

21st Feb 2025
DEMG:JPJ
ISIN: GB0059337583

DELTEX MEDICAL GROUP PLC
("Deltex Medical" or the "Group")

Deltex Medical Group plc ordinary shares are admitted to JP Jenkins

London, UK – February 2025 – Deltex Medical Group plc (JPJ:DEMG) is pleased to announce that its ordinary shares will be admitted for trading on the JP Jenkins share dealing platform. (Deltex Medical Group plc, registered at Terminus Road, Chichester, West Sussex, PO19 8TX (Company No. 03902895).)

Deltex Medical uses proprietary haemodynamic monitoring technology to assist clinicians to improve outcomes for patients as well as increase throughput and capacity for hospitals.

The Group's flagship, world-leading, ultrasound-based oesophageal doppler monitoring ("ODM") is supported by 24 randomised control trials conducted on anaesthetised patients. As a result, the primary application for ODM is focussed on guiding therapy for patients undergoing elective surgery as well as sedated patients in intensive care. The Group's new, TrueVue monitor makes the use of the ODM technology more intuitive and provides augmented data on the haemodynamic status of each patient.

JP Jenkins provides a share trading venue for unlisted or unquoted companies, enabling shareholders and prospective investors to trade equity on a matched bargain basis. JP Jenkins operates as a trading name of InfnitX Limited and is an Appointed Representative of Prosper Capital LLP (FRN 453007). The indicative pricing for the ordinary shares, along with transaction history, will be available on the JP Jenkins website: <https://jpenkins.com>.

For further information, please contact:

Deltex Medical Group PLC

Investor Relations:

Tel: +44(0) 1243 774 837

investorinfo@deltexmedical.com

JP Jenkins Ltd

Veronika Oswald / Mason Doick

Tel: +44 (0) 207 469 0937

- END -